GSK PLC Raises 2023 Guidance After 2Q Net Profit Beat
26 July 2023 - 5:02PM
Dow Jones News
By Ian Walker
GSK PLC on Wednesday raised its full-year guidance after
reporting a more than doubled second-quarter net profit which beat
market forecasts.
The British pharmaceutical giant attributed its performance to
strong sales in HIV and vaccines together with continued
strengthening of its R&D pipeline and product portfolio.
GSK made a net profit from continuing operations for the second
quarter of 1.62 billion pounds ($2.09 billion) compared with GBP706
million a year earlier and a company-compiled consensus of GBP1.41
billion.
Turnover for the period rose to GBP7.18 billion compared with
GBP6.93 billion, beating analysts' expectations of GBP6.77
billion.
Second-quarter adjusted operating profit--one of the company's
preferred metrics which strips out exceptional and other one-off
items--was GBP2.17 billion, compared with GBP2.01 billion the year
prior, while adjusted earnings per share from continuing operations
were 40.1 pence compared with 34.7 pence.
For the year ahead, GSK expects turnover to increase between 8%
and 10%, compared with previous guidance of 6%-8%, and adjusted
operating profit to increase between 11% and 13%, up from 10% and
12%. Adjusted earnings per share are forecast to rise between 14%
and 17% compared with previous guidance of 12% and 15%.
GSK has declared a second-quarter dividend of 14 pence a share
and said that it expects to pay 56.5 pence for the full year.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
July 26, 2023 02:47 ET (06:47 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Sep 2024 to Oct 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2023 to Oct 2024